General Information of Drug (ID: DMJ56XU)

Drug Name
ISIS 133726 Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMJ56XU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS-CRPRx DML84CN Coronary artery disease BA80 Phase 2 [2]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [3]
ISIS 133712 DMDZ3FU Discovery agent N.A. Investigative [1]
ISIS 140180 DMP9WOZ Discovery agent N.A. Investigative [1]
ISIS 330031 DM35WFL Discovery agent N.A. Investigative [1]
ISIS 330012 DMWIVS9 Discovery agent N.A. Investigative [1]
ISIS 329956 DMA96KW Discovery agent N.A. Investigative [1]
Phosphocholine DMIZLVW Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CRP messenger RNA (CRP mRNA) TTWRN6M CRP_HUMAN Not Available [1]

References

1 US patent application no. 7,425,545, Modulation of C-reactive protein expression.
2 Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):49-60.
3 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.